Agalsidase Beta
ATC A16AB04 · 11 markets · 20 records
AU 3 records · 3 strengths
- 35 mginjectionFABRAZYME agalsidase beta-rch 35mg powder for injection vial
- 5.5 mginjectionFABRAZYME agalsidase beta-rch 35mg powder for injection vial
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
US 2 records · 1 strengths
- 5 mginjectionFabrazyme
GB 2 records · 2 strengths
CA 2 records · 2 strengths
SG 2 records · 1 strengths
2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
ES 2 records · 2 strengths
TW 2 records · 2 strengths
- 35 mginjectionFABRAZYME Injection 5mg/vial法布瑞酶凍晶注射劑35毫克/小瓶
- 5 mginjectionFABRAZYME Injection 5mg/vial法布瑞酶凍晶注射劑5毫克/小瓶
HK 2 records · 1 strengths
2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 strengths
- 35 mginjectionFABRAZYME 35 mg, poudre pour solution à diluer pour perfusion
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | HK | EU | FR |
|---|---|---|---|---|---|---|---|---|---|---|
| 35 mg injection | Fabrazyme 5mg powder for concentrate for solution for infusion vials | FABRAZYME agalsidase beta-rch 35mg powder for injection vial | Fabrazyme | FABRAZYME Injection 5mg/vial 法布瑞酶凍晶注射劑35毫克/小瓶 | FABRAZYME 35 mg, poudre pour solution à diluer pour perfusion | |||||
| 5 mg injection | Fabrazyme | Fabrazyme 5mg powder for concentrate for solution for infusion vials | Fabrazyme | FABRAZYME Injection 5mg/vial 法布瑞酶凍晶注射劑5毫克/小瓶 | ||||||
| 5.5 mg injection | FABRAZYME agalsidase beta-rch 35mg powder for injection vial | |||||||||
| 35 mg powder | Fabrazyme | |||||||||
| 5 mg powder | Fabrazyme | |||||||||
unknown | Fabrazyme | FABRAZYME FOR INJ 35MG | Fabrazyme | |||||||
injection | Fabrazyme ® 5mg (agalsidase beta) |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
3 more strength/form rows are recorded only in CA · SG and are not shown in this table. Hay 3 filas de concentración/forma registradas solo en CA · SG que no se muestran en esta tabla. 另有 3 个规格/剂型仅在 CA · SG 有记录(未在本表显示)。 另有 3 個規格/劑型僅在 CA · SG 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.